Mizuho Medy Co., Ltd. (4595) AI Stock Analysis

• Market Cap: ¥30.00B
• Dividend Yield: 6.36%
• Average Volume (3M): 116.08K
• Price to Earnings (P/E): 9.1
• Beta (1Y): 0.40
• Revenue Growth: -3.11%
• EPS Growth: -13.09%
• Country: JP
• Employees: 187
• Sector: Healthcare
• Sector Strength: 51
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 12.78
• Shares Outstanding: 19,051,200
• 10 Day Avg. Volume: 92,970
• 30 Day Avg. Volume: 116,080
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: ―

Overall, Mizuho Medy Co., Ltd. exhibits strong financial performance with excellent balance sheet strength and profitability. Despite the positive valuation metrics, technical indicators suggest a bearish trend, which could pose a risk. The stock's low P/E ratio and high dividend yield are attractive, but the current price trends indicate caution.

Mizuho Medy Co., Ltd. Business Overview & Revenue Model

Company Description

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. The company was incorporated in 1977 and is headquartered in Tosu, Japan.

How the Company Makes Money

Mizuho Medy Co., Ltd. generates revenue through the sale of its medical devices and healthcare products. The company targets hospitals, clinics, and other healthcare facilities as its primary customer base, supplying them with essential medical equipment and consumables. Revenue is driven by the continuous demand for high-quality and reliable medical devices, which are crucial for patient care and medical procedures. The company may also engage in partnerships or collaborations with other healthcare organizations to expand its product offerings and reach a wider market. Additionally, Mizuho Medy Co., Ltd. may benefit from ongoing advancements in medical technology, which can lead to the development of new products and open up additional revenue streams.

Mizuho Medy Co., Ltd. Financial Statement Overview

Summary

Mizuho Medy Co., Ltd. demonstrates strong financial health with robust profitability, excellent balance sheet strength, and effective cash flow management. The income statement shows strong profitability with consistent gross and net profit margins. The balance sheet is very strong with zero debt and a high equity ratio, reflecting excellent financial stability. Cash flow indicates positive free cash flow, though it declined from 2023 to 2024.

Income Statement

The income statement shows strong profitability with consistent gross and net profit margins. Gross profit margin remained high at approximately 70.7% in 2024, and net profit margin was also strong at 33.0%. Revenue grew by 4.0% from 2023 to 2024, indicating steady growth. EBIT and EBITDA margins were robust at 43.0% and 45.0%, respectively, highlighting efficient operations.

Balance Sheet

The balance sheet is very strong with zero debt and a high equity ratio of 83.7% in 2024, reflecting excellent financial stability. Return on Equity (ROE) was impressive at 21.7%, showing effective use of shareholder funds. The high level of cash and short-term investments enhances liquidity and risk resilience.

Cash Flow

The cash flow statement indicates positive free cash flow, though it declined by 18.1% from 2023 to 2024. The operating cash flow to net income ratio was 0.89, indicating good cash generation from operations. However, the free cash flow to net income ratio also suggests a solid conversion of profits into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.34B	11.43B	10.99B	17.58B	12.89B	4.20B
Gross Profit	8.03B	8.08B	8.07B	14.10B	9.65B	2.76B
EBITDA	4.90B	5.15B	5.35B	11.23B	7.00B	611.11M
Net Income	3.58B	3.77B	3.77B	7.84B	4.82B	306.35M
Balance Sheet
Total Assets	20.14B	20.73B	18.95B	19.10B	12.19B	6.05B
Cash, Cash Equivalents and Short-Term Investments	11.02B	11.25B	10.13B	8.70B	4.33B	54.31M
Total Debt	0.00	0.00	0.00	0.00	0.00	593.34M
Total Liabilities	3.15B	3.38B	3.27B	4.82B	4.16B	2.27B
Stockholders Equity	16.99B	17.35B	15.68B	14.28B	8.03B	3.78B
Cash Flow
Free Cash Flow	0.00	3.05B	3.72B	5.99B	5.44B	198.36M
Operating Cash Flow	0.00	3.35B	3.99B	6.17B	5.60B	295.42M
Investing Cash Flow	0.00	-307.00M	-270.45M	-1.55B	-159.74M	-97.32M
Financing Cash Flow	0.00	-2.09B	-2.38B	-1.57B	-1.16B	-361.10M

Mizuho Medy Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1573.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Positive. The current price of 1573 is above the 20-day moving average (MA) of 1548.05, above the 50-day MA of 1470.90, and above the 200-day MA of 1456.68, indicating a bullish trend. The MACD of 32.29 indicates Positive momentum. The RSI at 65.50 is Neutral, neither overbought nor oversold. The STOCH value of 26.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4595.

Mizuho Medy Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4595	71 Outperform	¥30.00B	9.07		6.36%	-3.11%	-13.09%
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
FUP	―	€213.25M	11.27	7.10%	―	―	―
4569	77 Outperform	¥80.49B	8.56		3.39%	9.83%	86.18%
4886	74 Outperform	¥68.39B	14.20		1.97%	6.23%	-31.45%
4577	70 Outperform	¥37.07B	19.66		4.26%	7.99%	-51.78%
4538	58 Neutral	¥19.04B	6.46		3.76%	8.71%	-325.91%